Group 1: Maternity Healthcare Challenges - In Illinois, 34.3% of counties are classified as maternity healthcare deserts, requiring residents to travel between 47 and 59 miles to reach a birthing hospital [1] - Many rural hospitals in Illinois have closed their labor and delivery units, exacerbating the issue of maternity care deserts [3] Group 2: OSF OnCall Connect Program - The OSF OnCall Connect program aims to provide pregnancy and postpartum care to women on Medicaid in Central Illinois, particularly in underserved counties [2][3] - The program includes a mobile clinic that will offer prenatal and postpartum services, including sonograms, lab work, vaccinations, and blood pressure monitoring [1][3] Group 3: Operational Details - The mobile unit is set to begin operations in July 2025, with eligible patients able to self-enroll or be referred by their healthcare provider [3] - The OSF OnCall Connect team will assist with program enrollment and scheduling appointments for the mobile clinic [3] Group 4: Services Offered - Services provided by the mobile clinic include education and information for each week of pregnancy, regular check-ins, 24/7 virtual access to a care team, blood pressure monitoring, lab work, screening for postpartum depression, and breastfeeding support [8]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors regarding its revenue outlook and growth projections during the Class Period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Centene securities during the specified Class Period [1]. - Investors have until September 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Centene - The complaint alleges that Centene created a false impression of having reliable information about its projected revenue and growth while promoting high enrollment rates and low morbidity [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share, marking a decline of over 40% [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly providing misleading information regarding its expected revenue and earnings during the Class Period from December 12, 2024, to June 30, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided investors with overly positive statements about enrollment and morbidity rates while concealing adverse facts about the company's true performance [5]. - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its business prospects and financial guidance [1][2]. Allegations - The complaint claims that Centene's management created a false impression of reliable information regarding projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [2]. - A preliminary analysis indicated that over two-thirds of Centene's marketplace share showed disappointing enrollment and increased morbidity, contradicting the company's optimistic reports [2]. Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states was lower than anticipated, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share, marking a decline of over 40% in just one day [3].

SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene as well as certain of Centene’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene cl ...

Core Viewpoint - DJS Law Group is investigating Centene Corporation for potential violations of securities laws following a significant drop in its stock price after the company withdrew its financial guidance for 2025, indicating earnings would fall short of expectations [1]. Investigation Details - The investigation centers on whether Centene made misleading statements or failed to disclose critical information to investors [1]. - Following the announcement, Centene's shares plummeted by 36.6% in morning trading on July 2, 2025 [1]. Company Background - Centene Corporation is identified as a managed-care giant, indicating its significant role in the healthcare sector [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price following the withdrawal of 2025 guidance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Centene between December 12, 2024, and June 30, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Company Performance and Stock Impact - Centene's stock price fell dramatically from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [5]. - The company announced a reduction in its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75, following a disappointing analysis of its market growth [4]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit-sub ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].